Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sandoz Group AGXSWX:SDZ -0.16%11 Earnings Yield (Joel Greenblatt) % is 4.04% as of Dec. 2025, which is 156% above its 10-year median of 1.58. GuruFocus rates XSWX:SDZ with a GF Score™ of 11/100. The stock has 3 warning signs investors should review. Among 1,012 Drug Manufacturers companies, Sandoz Group AG ranks better than 52.57% on this metric.
Sandoz Group AG's Enterprise Value for the quarter that ended in Dec. 2025 was CHF28,171 Mil.
Sandoz Group AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF1,147 Mil. Sandoz Group AG's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 4.04%.
The historical rank and industry rank for Sandoz Group AG's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
XSWX:SDZ'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 0.75 Med: 1.58 Max: 10.36
Current: 3.73
During the past 4 years, the highest Earnings Yield (Joel Greenblatt) of Sandoz Group AG was 10.36%. The lowest was 0.75%. And the median was 1.58%.
XSWX:SDZ's Earnings Yield (Joel Greenblatt) % is ranked better than 52.57% of 1012
companies
in the Drug Manufacturers industry
Industry Median: 3.32
vs XSWX:SDZ: 3.73
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Sandoz Group AG's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Sandoz Group AG (XSWX:SDZ) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Sandoz Group AG Earnings Yield (Joel Greenblatt) % Related Terms
Sandoz Group AG Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Sandoz Group AG's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG Earnings Yield (Joel Greenblatt) % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's Earnings Yield (Joel Greenblatt) % falls into.
Sandoz Group AG Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Sandoz Group AGs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 4.04% mean?
Sandoz Group AG (XSWX:SDZ) has a Earnings Yield (Joel Greenblatt) % of 4.04% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Sandoz Group AG and its competitors. This is 156% above median its historical median of 1.58. Over the past decade, Sandoz Group AG's Earnings Yield (Joel Greenblatt) % has ranged from 0.75 to 10.36. According to the industry distribution chart, Sandoz Group AG ranks #480 out of 1012 companies in the Drug Manufacturers industry, placing it in the top 47.4%.
Is Sandoz Group AG's Earnings Yield (Joel Greenblatt) % too high?
Sandoz Group AG's current Earnings Yield (Joel Greenblatt) % of 4.04% is 156% above median its 10-year median of 1.58. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 10.36. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.32. Sandoz Group AG's value of 4.04% is 21.7% above this industry median. Based on the distribution chart, Sandoz Group AG ranks #480 out of 1012 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sandoz Group AG has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Earnings Yield (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandoz Group AG ranks #480 out of 1012 companies for Earnings Yield (Joel Greenblatt) %. This puts Sandoz Group AG in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.32. Sandoz Group AG's value of 4.04% is 21.7% above this benchmark. Historically, Sandoz Group AG's own Earnings Yield (Joel Greenblatt) % has ranged from 0.75 to 10.36 over the past decade. While the company's 10-year median is 1.58 vs. the industry median of 3.32, Sandoz Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.32, based on 1,012 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandoz Group AG's current Earnings Yield (Joel Greenblatt) % of 4.04% is 21.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Sandoz Group AG and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandoz Group AG's current Earnings Yield (Joel Greenblatt) % is 4.04%, which is 156% above median its own 10-year median of 1.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (XSWX:SDZ) has a current Earnings Yield (Joel Greenblatt) % of 4.04%. The current Earnings Yield (Joel Greenblatt) % is 4.04%, which is 156% above median its 10-year median of 1.58 and 21.7% above the Drug Manufacturers industry median of 3.32. Sandoz Group AG's overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Sandoz Group AG (XSWX:SDZ), the current Earnings Yield (Joel Greenblatt) % is 4.04% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
11GF Score
Get the complete analysis for XSWX:SDZ
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SDZ has been successfully added to your 
